Benzinga | Jul 24, 2020 05:09AM EDT

Baird Downgrades Arbutus Biopharma to Neutral

Baird analyst Madhu Kumar downgrades Arbutus Biopharma (NASDAQ:ABUS) from Outperform to Neutral.